No Data
Two Sessions Time | National People's Congress Representative, Lu Qingguo from Chenguang Biotech Group: Improve the quality standards of Chinese Patent Medicine, regulate the centralized procurement model for Traditional Chinese Medicine, and optimize the
① Lu Qingguo, Director of Chenguang Biotech Group and a representative of the National People's Congress, focused on several recommendations at this year's Two Sessions, including optimizing the procurement mechanism for Traditional Chinese Medicine, enhancing the quality standards for Chinese Patent Medicine, and standardizing the Traditional Chinese Medicine granule industry; ② In addition to recommendations related to the Traditional Chinese Medicine industry, Lu Qingguo prepared several suggestions on rural social retirement insurance, rural medical insurance, and increasing support for companies sanctioned by the United States.
Shijiazhuang Yiling Pharmaceutical Co., Ltd.'s (SZSE:002603) Top Owners Are Individual Investors With 34% Stake, While 32% Is Held by Private Companies
Shijiazhuang Yiling Pharmaceutical Co., Ltd.'s (SZSE:002603) Business Is Trailing The Industry But Its Shares Aren't
Eling Pharmaceutical: 2024 Annual Results Forecast
Shijiazhuang Yiling Pharmaceutical (002603.SZ) announced a preliminary loss, expecting a net loss of 0.6 billion to 0.8 billion yuan in 2024, turning from profit to loss year-on-year.
Shijiazhuang Yiling Pharmaceutical (002603.SZ) released its performance forecast for 2024, expecting the annual profit attributable to the Shareholders of the listed company...
Shijiazhuang Yiling Pharmaceutical (002603.SZ): The Traditional Chinese Medicine Innovative Drugs Qifang Nasal Passage Tablets have obtained the pharmaceutical registration certificate.
On January 21, Gelonghui reported that Shijiazhuang Yiling Pharmaceutical (002603.SZ) announced that recently, its wholly-owned subsidiary Peking Yiling Pharmaceutical Co., Ltd. (referred to as "Peking Yiling") received the "Pharmaceutical Registration Certificate" approved and issued by the National Medical Products Administration. The new drug marketing registration application for "Qi Fang Bi Tong Pian" submitted by Peking Yiling has been formally approved. "Qi Fang Bi Tong Pian" is a Class I Innovative Drug of Traditional Chinese Medicine independently developed by the company, used to treat persistent allergic rhinitis. Its main function is to benefit Qi and open the orifices. It is used to alleviate sneezing in patients with persistent allergic rhinitis of lung and spleen deficiency type who do not have seasonal allergens.
Benign Growth For Shijiazhuang Yiling Pharmaceutical Co., Ltd. (SZSE:002603) Underpins Its Share Price
